<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2022-03-11T00:57:47Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7894916" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7894916</identifier>
        <datestamp>2021-03-01</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7894916</article-id>
              <article-id pub-id-type="pmcid">PMC7894916</article-id>
              <article-id pub-id-type="pmc-uid">7894916</article-id>
              <article-id pub-id-type="pmid">33606802</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-20-30011</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247445</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immunity</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immunity</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Epidemiology</subject>
                    <subj-group>
                      <subject>Pandemics</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Response</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Response</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Computer and Information Sciences</subject>
                  <subj-group>
                    <subject>Data Management</subject>
                    <subj-group>
                      <subject>Data Visualization</subject>
                      <subj-group>
                        <subject>Infographics</subject>
                        <subj-group>
                          <subject>Graphs</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Infectious Diseases</subject>
                      <subj-group>
                        <subject>Viral Diseases</subject>
                        <subj-group>
                          <subject>Covid 19</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Public and Occupational Health</subject>
                    <subj-group>
                      <subject>Preventive Medicine</subject>
                      <subj-group>
                        <subject>Vaccination and Immunization</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>RNA viruses</subject>
                        <subj-group>
                          <subject>Coronaviruses</subject>
                          <subj-group>
                            <subject>SARS coronavirus</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Medical microbiology</subject>
                      <subj-group>
                        <subject>Microbial pathogens</subject>
                        <subj-group>
                          <subject>Viral pathogens</subject>
                          <subj-group>
                            <subject>Coronaviruses</subject>
                            <subj-group>
                              <subject>SARS coronavirus</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and health sciences</subject>
                  <subj-group>
                    <subject>Pathology and laboratory medicine</subject>
                    <subj-group>
                      <subject>Pathogens</subject>
                      <subj-group>
                        <subject>Microbial pathogens</subject>
                        <subj-group>
                          <subject>Viral pathogens</subject>
                          <subj-group>
                            <subject>Coronaviruses</subject>
                            <subj-group>
                              <subject>SARS coronavirus</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>Viral pathogens</subject>
                        <subj-group>
                          <subject>Coronaviruses</subject>
                          <subj-group>
                            <subject>SARS coronavirus</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Engineering and Technology</subject>
                  <subj-group>
                    <subject>Industrial Engineering</subject>
                    <subj-group>
                      <subject>Control Engineering</subject>
                      <subj-group>
                        <subject>Control Theory</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Computer and Information Sciences</subject>
                  <subj-group>
                    <subject>Systems Science</subject>
                    <subj-group>
                      <subject>Control Theory</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Physical Sciences</subject>
                  <subj-group>
                    <subject>Mathematics</subject>
                    <subj-group>
                      <subject>Systems Science</subject>
                      <subj-group>
                        <subject>Control Theory</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A control theory approach to optimal pandemic mitigation</article-title>
                <alt-title alt-title-type="running-head">A control theory approach to optimal pandemic mitigation</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4867-8542</contrib-id>
                  <name>
                    <surname>Godara</surname>
                    <given-names>Prakhar</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref ref-type="aff" rid="aff001"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Herminghaus</surname>
                    <given-names>Stephan</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3535-2773</contrib-id>
                  <name>
                    <surname>Heidemann</surname>
                    <given-names>Knut M.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001"/>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <addr-line>Max Planck Institute for Dynamics and Self-Organization, Göttingen, Germany</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Pluchino</surname>
                    <given-names>Alessandro</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>University of Catania, ITALY</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>knut.heidemann@ds.mpg.de</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>19</day>
                <month>2</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>19</day>
                <month>2</month>
                <year>2021</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
              <volume>16</volume>
              <issue>2</issue>
              <elocation-id>e0247445</elocation-id>
              <history>
                <date date-type="received">
                  <day>23</day>
                  <month>9</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>6</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 Godara et al</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Godara et al</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0247445.pdf"/>
              <abstract>
                <p>In the framework of homogeneous susceptible-infected-recovered (SIR) models, we use a control theory approach to identify optimal pandemic mitigation strategies. We derive rather general conditions for reaching herd immunity while minimizing the costs incurred by the introduction of societal control measures (such as closing schools, social distancing, lockdowns, etc.), under the constraint that the infected fraction of the population does never exceed a certain maximum corresponding to public health system capacity. Optimality is derived and verified by variational and numerical methods for a number of model cost functions. The effects of immune response decay after recovery are taken into account and discussed in terms of the feasibility of strategies based on herd immunity.</p>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004189</institution-id>
                      <institution>Max-Planck-Gesellschaft</institution>
                    </institution-wrap>
                  </funding-source>
                  <principal-award-recipient>
                    <name>
                      <surname>Herminghaus</surname>
                      <given-names>Stephan</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004189</institution-id>
                      <institution>Max-Planck-Gesellschaft</institution>
                    </institution-wrap>
                  </funding-source>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3535-2773</contrib-id>
                    <name>
                      <surname>Heidemann</surname>
                      <given-names>Knut M.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004189</institution-id>
                      <institution>Max-Planck-Gesellschaft</institution>
                    </institution-wrap>
                  </funding-source>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4867-8542</contrib-id>
                    <name>
                      <surname>Godara</surname>
                      <given-names>Prakhar</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>P. G., S. H., and K. M. H. gratefully acknowledge support from the Max Planck Society.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="6"/>
                <table-count count="0"/>
                <page-count count="16"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All data files and code are available on github: <ext-link ext-link-type="uri" xlink:href="https://github.com/poss-group/covid19-control">https://github.com/poss-group/covid19-control</ext-link>.</meta-value>
                </custom-meta>
                <custom-meta id="outbreaks">
                  <meta-name>Outbreaks</meta-name>
                  <meta-value>COVID-19</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All data files and code are available on github: <ext-link ext-link-type="uri" xlink:href="https://github.com/poss-group/covid19-control">https://github.com/poss-group/covid19-control</ext-link>.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>The recent outbreak of the illness COVID-19, caused by the SARS-CoV-2 virus, has resulted in a pandemic with unprecedented impact on societies all over the globe. Mitigation measures included complete lockdowns of societal life, with severe psychic, social, and economic consequences [<xref rid="pone.0247445.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0247445.ref002" ref-type="bibr">2</xref>]. Hence a major focus of governments is on designing containment strategies which are as mild as possible, but substantial enough to limit the severity of the outbreak in order not to overwhelm the health service system (HSS). This requires reliable forecast, based on careful collection of data on the fraction of infected citizens, as well as extensive simulation [<xref rid="pone.0247445.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0247445.ref003" ref-type="bibr">3</xref>].</p>
              <p>We discuss the system in terms of a so-called SIR model [<xref rid="pone.0247445.ref004" ref-type="bibr">4</xref>], referring to the fraction of susceptible (S), infected (I), and recovered (R) citizens in the population. We identify the recovered with all those who are neither susceptible nor infected (<italic>R</italic> = 1 − <italic>S</italic> − <italic>I</italic>); the dynamics are thus fully described by a set of two equations:
<disp-formula id="pone.0247445.e001"><alternatives><graphic xlink:href="pone.0247445.e001.jpg" id="pone.0247445.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>∂</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mi>S</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>−</mml:mo><mml:mi>β</mml:mi><mml:mi>S</mml:mi><mml:mi>I</mml:mi><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd/></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>∂</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mi>I</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi>β</mml:mi><mml:mi>S</mml:mi><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:mfrac><mml:mi>I</mml:mi><mml:mi>τ</mml:mi></mml:mfrac><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(1)</label></disp-formula>
where <italic>S</italic>, <italic>I</italic> ∈ [0, 1] are the fraction of susceptible and infected individuals in the population, respectively. Note that <italic>I</italic>(<italic>t</italic>) denotes the actual fraction of acutely infected citizens at time <italic>t</italic>, no matter whether or not the infection has been realized by the individual, or has even been recorded. The infection of a susceptible individual by an infected is described by the <italic>infection rate β</italic> &gt; 0, while <italic>τ</italic> is the <italic>average duration</italic> of the infection of an individual until her recovery.</p>
              <p>The task we address in this study is to limit, during the whole period of the pandemic, the current number of infected individuals such as to prevent the number of those needing intensive care from exceeding the capacity of the deployed HSS. Such control may be described by a control parameter <italic>α</italic>(<italic>t</italic>), which quantifies the effect of mitigation strategies upon the infection rate. We may write <italic>β</italic> = <italic>β</italic><sub>0</sub>(1 − <italic>α</italic>), such that <italic>α</italic> = 0 and <italic>α</italic> = 1 correspond to usual societal life and complete mutual isolation of citizens, respectively.</p>
              <p>In order to define <italic>α</italic> in a general way, we state that a certain value of <italic>α</italic> = 1 − <italic>β</italic>/<italic>β</italic><sub>0</sub> denotes the subset of all possible mitigation measures which lead to an infection rate <italic>β</italic> ≤ <italic>β</italic><sub>0</sub>. We thus do not need to refer to any specific measures, but can formulate our approach in a very general way. The (more or less) accurate determination of these subsets is then the task of careful social (e.g., infection history) data analysis among citizens. This is illustrated in <xref ref-type="fig" rid="pone.0247445.g001">Fig 1</xref>, where mitigation strategies, followed by the public authorities, are indicated by the dashed and dotted curves, within a space spanned by the effect of the measures upon the infection rate, <italic>α</italic>, and the cost incurred for economy and society as a whole, <italic>f</italic>(<italic>α</italic>).</p>
              <fig id="pone.0247445.g001" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0247445.g001</object-id>
                <label>Fig 1</label>
                <caption>
                  <title>Space of mitigation measures.</title>
                  <p>Sketch of the space of possible mitigation measures (grey shade), spanned by their effect on the infection rate, <italic>α</italic>, and their socio-economic cost, <italic>f</italic>(<italic>α</italic>). Normal societal life is at the origin, while the upper right corner corresponds to total mutual isolation of all citizens, which is the strongest possible intervention. The dashed and dotted curves depict possible choices for mitigation measures. Such curves correspond to the <italic>cost functions</italic> referred to in the manuscript (see <xref ref-type="disp-formula" rid="pone.0247445.e007">Eq (7)</xref>.</p>
                </caption>
                <graphic xlink:href="pone.0247445.g001"/>
              </fig>
              <p>As indicated by the explicit time dependence of <italic>α</italic>(<italic>t</italic>), we follow a control theoretic approach. This is in some contrast to earlier treatments which have assumed mitigation measures to be constant over time [<xref rid="pone.0247445.ref005" ref-type="bibr">5</xref>–<xref rid="pone.0247445.ref008" ref-type="bibr">8</xref>]. Instead, we aim at determining the optimal function <italic>α</italic>(<italic>t</italic>) which minimizes the impact on society, while at the same time avoiding the HSS to become overloaded. At the end of the mitigation scenario, <italic>herd immunity</italic> shall be reached, so that the epidemic comes to an end without further control. We do not consider potential vaccination scenarios here (as is done elsewhere [<xref rid="pone.0247445.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0247445.ref010" ref-type="bibr">10</xref>]), so immunization can only be achieved via infection with the virus in the present study.</p>
              <p>A dimensionless quantity which is frequently used in epidemiology is the <italic>reproduction number</italic>, <italic>R</italic> ≔ <italic>βτS</italic>, which denotes the average number of susceptibles infected by one infected individual. At the beginning of an epidemic (<italic>S</italic> ≈ 1) and without mitigation measures deployed (<italic>β</italic> = <italic>β</italic><sub>0</sub>), one observes the <italic>basic</italic> reproduction number <italic>R</italic><sub>0</sub> = <italic>β</italic><sub>0</sub><italic>τ</italic>. In case of the COVID-19 pandemic, typical estimates are <italic>R</italic><sub>0</sub> ≈ 3 [<xref rid="pone.0247445.ref011" ref-type="bibr">11</xref>] and <italic>τ</italic> ≈ ten days [<xref rid="pone.0247445.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0247445.ref012" ref-type="bibr">12</xref>]. It has been shown before that the inherently random, network-like structure of interactions between individuals mainly results in a readjustment of <italic>R</italic><sub>0</sub> [<xref rid="pone.0247445.ref013" ref-type="bibr">13</xref>]. Hence we follow a mean field approach, disregarding small scale inhomogeneities of the system. We consider a homogeneous scenario, where <italic>β</italic>(<italic>t</italic>) depends on time, but is spatially constant. Defining a normalized time variable, <italic>θ</italic> ≔ <italic>βt</italic>, we can rewrite <xref ref-type="disp-formula" rid="pone.0247445.e001">Eq (1)</xref> as
<disp-formula id="pone.0247445.e002"><alternatives><graphic xlink:href="pone.0247445.e002.jpg" id="pone.0247445.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>∂</mml:mi><mml:mi>θ</mml:mi></mml:msub><mml:mi>S</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>−</mml:mo><mml:mi>S</mml:mi><mml:mi>I</mml:mi><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd/></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>∂</mml:mi><mml:mi>θ</mml:mi></mml:msub><mml:mi>I</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi>S</mml:mi><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:mfrac><mml:mi>I</mml:mi><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(2)</label></disp-formula>
The trajectory of the system in the <italic>S</italic>-<italic>I</italic>-plane, <italic>I</italic>(<italic>S</italic>), can be obtained by dividing the equations displayed in <xref ref-type="disp-formula" rid="pone.0247445.e002">Eq (2)</xref> by each other. This yields
<disp-formula id="pone.0247445.e003"><alternatives><graphic xlink:href="pone.0247445.e003.jpg" id="pone.0247445.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(3)</label></disp-formula>
which has the solution:
<disp-formula id="pone.0247445.e004"><alternatives><graphic xlink:href="pone.0247445.e004.jpg" id="pone.0247445.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M4"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>I</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>S</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo form="prefix">ln</mml:mo><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi>C</mml:mi><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(4)</label></disp-formula>
where <italic>C</italic> is a constant of integration. When no mitigation measures are in place (<italic>α</italic> = 0), we have <italic>I</italic>(1) = 0 and thus obtain
<disp-formula id="pone.0247445.e005"><alternatives><graphic xlink:href="pone.0247445.e005.jpg" id="pone.0247445.e005g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M5"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>I</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>S</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo form="prefix">ln</mml:mo><mml:mi>S</mml:mi></mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(5)</label></disp-formula>
This is plotted as the dashed curve in <xref ref-type="fig" rid="pone.0247445.g002">Fig 2</xref> for the case <italic>R</italic><sub>0</sub> = 3. The maximum turns out to occur at <italic>S</italic><sub>peak</sub> = 1/<italic>R</italic><sub>0</sub>, where it reaches a value of
<disp-formula id="pone.0247445.e006"><alternatives><graphic xlink:href="pone.0247445.e006.jpg" id="pone.0247445.e006g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M6"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mtext>peak</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mo form="prefix">ln</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(6)</label></disp-formula>
At <italic>S</italic> = <italic>S</italic><sub>peak</sub> = 1/<italic>R</italic><sub>0</sub>, the population has reached <italic>herd immunity</italic> since from then on the number of infected citizens decreases until zero.</p>
              <fig id="pone.0247445.g002" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0247445.g002</object-id>
                <label>Fig 2</label>
                <caption>
                  <title>Trajectories in the (<italic>S</italic>, <italic>I</italic>)-plane.</title>
                  <p>Dashed curve: trajectory with no mitigation starting at (<italic>S</italic>, <italic>I</italic>) = (1, 0), <italic>R</italic><sub>0</sub> = 3. Horizontal dashed line: maximum load of the HSS, <italic>I</italic><sub><italic>h</italic></sub> (here we have set <italic>I</italic><sub><italic>h</italic></sub> = 0.1 for clarity, although this is unrealistically large). Solid curve: trajectory, (<italic>S</italic>*(<italic>t</italic>), <italic>I</italic>*(<italic>t</italic>)), for an optimal choice of <italic>α</italic>(<italic>t</italic>) (see <xref ref-type="disp-formula" rid="pone.0247445.e019">Eq 16</xref>). The corresponding characteristic of <italic>α</italic>(<italic>S</italic>) follows the dash-dotted curve in phase II, the <italic>mitigation phase</italic>. There is no mitigation in phases I and III (<italic>α</italic> = 0).</p>
                </caption>
                <graphic xlink:href="pone.0247445.g002"/>
              </fig>
              <p>If the disease is serious, one is faced with the problem that with a fraction of <italic>I</italic><sub>peak</sub> people being infected, the number of those in need of hospitalization or even intense care may exceed the capacity of the HSS. We denote by <italic>I</italic><sub><italic>h</italic></sub> &lt; <italic>I</italic><sub>peak</sub> the maximum fraction of infected citizens which can be managed by the HSS. It is limited by infrastructural aspects, such as the availability of staff or the size and areal density of hospitals, and is indicated by the horizontal dotted line in <xref ref-type="fig" rid="pone.0247445.g002">Fig 2</xref>. Any substantial overshoot of the dashed curve over the dotted line constitutes a catastrophe, as a major fraction of the population will then not receive proper health care or treatment. This must clearly be avoided by means of suitable measures, such as reducing mutual contacts between individuals, banning major assemblies, reducing mobility etc., thus reducing the infection rate. Such measures are described by the parameter <italic>α</italic>(<italic>t</italic>), which is to be discussed next.</p>
            </sec>
            <sec id="sec002">
              <title>Optimal control problem</title>
              <p>It is clear that the aforementioned measures will have a more or less substantial impact on society, mainly through their detrimental effects on economy, but also through other societal (e.g., cultural) damage. This may be described by means of a <italic>cost functional</italic>, 
<disp-formula id="pone.0247445.e007"><alternatives><graphic xlink:href="pone.0247445.e007.jpg" id="pone.0247445.e007g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M7"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>K</mml:mi><mml:mo>{</mml:mo><mml:mi>α</mml:mi><mml:mo>}</mml:mo><mml:mo>≔</mml:mo><mml:mo>∫</mml:mo><mml:mi>f</mml:mi><mml:mo>(</mml:mo><mml:mi>α</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo><mml:mspace width="0.166667em"/><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(7)</label></disp-formula>
where the cost function <italic>f</italic> corresponds to the mitigation strategy chosen, i.e., the curve chosen in <xref ref-type="fig" rid="pone.0247445.g001">Fig 1</xref>. It denotes the cost incurred at a given control <italic>α</italic>, along with the assumption ∂<italic>f</italic>/∂<italic>α</italic> ≥ 0 ∀<italic>α</italic>; later we will require <inline-formula id="pone.0247445.e008"><alternatives><graphic xlink:href="pone.0247445.e008.jpg" id="pone.0247445.e008g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M8"><mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mi>∂</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>∂</mml:mi><mml:msup><mml:mi>α</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. Convexity of the cost function is a reasonable assumption since one can imagine that chosen mitigation measures become more and more costly as <italic>α</italic> approaches unity. In principle, <italic>f</italic>(⋅) could depend on time <italic>t</italic> explicitly or involve memory, e.g., because prolonged measures cause disproportinally higher cost. For simplicity, we do not treat such cases here.</p>
              <p>The control problem we choose to address is to find a control trajectory, denoted by the function <italic>α</italic>(<italic>t</italic>), such that the impact on society, as described by <italic>K</italic>, is being minimized under the constraint that <italic>I</italic>(<italic>t</italic>) never exceeds <italic>I</italic><sub><italic>h</italic></sub> (capacity of the HSS) and at the end of mitigation—at <italic>unknown</italic> terminal time <italic>t</italic><sub><italic>e</italic></sub>—herd immunity is reached, i.e., <italic>S</italic>(<italic>t</italic><sub><italic>e</italic></sub>) = 1/<italic>R</italic><sub>0</sub> (end of phase II in <xref ref-type="fig" rid="pone.0247445.g002">Fig 2</xref>).</p>
              <p>We thus need to
<disp-formula id="pone.0247445.e009"><alternatives><graphic xlink:href="pone.0247445.e009.jpg" id="pone.0247445.e009g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M9"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mtext>minimize</mml:mtext><mml:mspace width="1em"/></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi>K</mml:mi><mml:mrow><mml:mo>{</mml:mo><mml:mi>α</mml:mi><mml:mo>}</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∫</mml:mo><mml:mn>0</mml:mn><mml:msub><mml:mi>t</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.166667em"/><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mtext>such</mml:mtext><mml:mspace width="4pt"/><mml:mtext>that</mml:mtext><mml:mspace width="1em"/></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>,</mml:mo><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo><mml:mspace width="0.166667em"/><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mi>I</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>≤</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo><mml:mspace width="0.166667em"/><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(8)</label></disp-formula>
where <italic><bold>x</bold></italic> = (<italic>S</italic>, <italic>I</italic>), and <italic><bold>h</bold></italic>(<italic><bold>x</bold></italic>, <italic>α</italic>(<italic>t</italic>)) as given by <xref ref-type="disp-formula" rid="pone.0247445.e001">Eq 1</xref> (with <italic>β</italic> = <italic>β</italic><sub>0</sub>(1 − <italic>α</italic>)). Minimization of mitigation time is covered by setting <italic>f</italic>(⋅) ≡ <italic>const</italic>.</p>
              <p>Solving <xref ref-type="disp-formula" rid="pone.0247445.e009">Eq 8</xref> can be recast into minimization of the following functional:
<disp-formula id="pone.0247445.e010"><alternatives><graphic xlink:href="pone.0247445.e010.jpg" id="pone.0247445.e010g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M10"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>J</mml:mi><mml:mo>≔</mml:mo><mml:msubsup><mml:mo>∫</mml:mo><mml:mn>0</mml:mn><mml:msub><mml:mi>t</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mo mathvariant="bold">λ</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>·</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mover accent="true"><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>,</mml:mo><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>μ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.166667em"/><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(9)</label></disp-formula>
where <bold>λ</bold>(<italic>t</italic>) = (λ<sub><italic>S</italic></sub>(<italic>t</italic>), λ<sub><italic>I</italic></sub>(<italic>t</italic>)), <italic>μ</italic>(<italic>t</italic>)) are Lagrange multipliers. The introduction of <italic>μ</italic>(<italic>t</italic>) for the inequality constraint introduces additional constraints on <italic>μ</italic>(<italic>t</italic>), namely <italic>μ</italic>(<italic>t</italic>) ≥ 0 and the complementary slackness condition <italic>μ</italic>(<italic>t</italic>)(<italic>I</italic>* − <italic>I</italic><sub><italic>h</italic></sub>) = 0. These are also known as KKT conditions [<xref rid="pone.0247445.ref014" ref-type="bibr">14</xref>]. The star (*) represents the optimal quantities. Additionally, <italic>S</italic>(<italic>t</italic><sub><italic>e</italic></sub>) = 1/<italic>R</italic><sub>0</sub> and <italic><bold>x</bold></italic>(0) = <italic>x</italic><sub>0</sub> need to be enforced.</p>
              <p>The necessary conditions for optimality can be evaluated by setting the first variation of <xref ref-type="disp-formula" rid="pone.0247445.e010">Eq 9</xref> to zero (for a detailed derivation see <xref ref-type="supplementary-material" rid="pone.0247445.s001">S1 Appendix</xref>), we obtain:
<disp-formula id="pone.0247445.e011"><alternatives><graphic xlink:href="pone.0247445.e011.jpg" id="pone.0247445.e011g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M11"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mi>α</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mo mathvariant="bold">λ</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>·</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:msup><mml:mi>α</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(10)</label></disp-formula>
<disp-formula id="pone.0247445.e012"><alternatives><graphic xlink:href="pone.0247445.e012.jpg" id="pone.0247445.e012g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M12"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mover accent="true"><mml:mo mathvariant="bold">λ</mml:mo><mml:mo>˙</mml:mo></mml:mover><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mo mathvariant="bold">λ</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>·</mml:mo><mml:msub><mml:mo mathvariant="bold">∇</mml:mo><mml:mi mathvariant="bold-italic">x</mml:mi></mml:msub><mml:mi mathvariant="bold-italic">h</mml:mi><mml:msub><mml:mrow><mml:msub><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>μ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.166667em"/><mml:msub><mml:mo mathvariant="bold">∇</mml:mo><mml:mi mathvariant="bold-italic">x</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(11)</label></disp-formula>
<disp-formula id="pone.0247445.e013"><alternatives><graphic xlink:href="pone.0247445.e013.jpg" id="pone.0247445.e013g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M13"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>∂</mml:mi><mml:mi>α</mml:mi></mml:msub><mml:mi>f</mml:mi><mml:msub><mml:mrow><mml:msub><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mi>α</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mo mathvariant="bold">λ</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>·</mml:mo><mml:msub><mml:mi>∂</mml:mi><mml:mi>α</mml:mi></mml:msub><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mi>α</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(12)</label></disp-formula>
<disp-formula id="pone.0247445.e014"><alternatives><graphic xlink:href="pone.0247445.e014.jpg" id="pone.0247445.e014g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M14"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mo>λ</mml:mo><mml:mi>I</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(13)</label></disp-formula>
<disp-formula id="pone.0247445.e015"><alternatives><graphic xlink:href="pone.0247445.e015.jpg" id="pone.0247445.e015g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M15"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>≥</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(14)</label></disp-formula>
<disp-formula id="pone.0247445.e016"><alternatives><graphic xlink:href="pone.0247445.e016.jpg" id="pone.0247445.e016g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M16"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>μ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(15)</label></disp-formula>
In addition to these, one also has the optimal system dynamics <inline-formula id="pone.0247445.e017"><alternatives><graphic xlink:href="pone.0247445.e017.jpg" id="pone.0247445.e017g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M17"><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mo>*</mml:mo></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>α</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>. The necessary conditions become sufficient conditions if <italic><bold>h</bold></italic>(<italic>x</italic>, <italic>α</italic>) and <italic>f</italic>(<italic>α</italic>) are convex in <italic>x</italic> and <italic>α</italic> [<xref rid="pone.0247445.ref015" ref-type="bibr">15</xref>]. The former can be checked to be valid for the SIR model and the latter implies that <inline-formula id="pone.0247445.e018"><alternatives><graphic xlink:href="pone.0247445.e018.jpg" id="pone.0247445.e018g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M18"><mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mi>∂</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>∂</mml:mi><mml:msup><mml:mi>α</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>.</p>
              <p>The task remains to find Lagrange multipliers <bold>λ</bold>(<italic>t</italic>) and <italic>μ</italic>(<italic>t</italic>) which simultaneously satisfy the above conditions. This task usually involves a numerical search for the initial conditions of the Lagrange multipliers and evolve the system of ODE’s until the terminal conditions given by Eqs <xref ref-type="disp-formula" rid="pone.0247445.e011">10</xref> and <xref ref-type="disp-formula" rid="pone.0247445.e014">13</xref> are met. We escape the numerical difficulties arising with this procedure by first guessing a solution and then finding the appropriate Lagrange multipliers which verify optimality.</p>
              <sec id="sec003">
                <title>Heuristic approach</title>
                <p>Let us first consider what is necessary to keep the fraction of infected citizens at a constant value, <italic>I</italic><sub><italic>c</italic></sub>. Since <italic>S</italic> varies with time, <italic>dI</italic>/<italic>dt</italic> = 0 entails <italic>dI</italic>/<italic>dS</italic> = 0, and hence from <xref ref-type="disp-formula" rid="pone.0247445.e003">Eq 3</xref> we obtain
<disp-formula id="pone.0247445.e019"><alternatives><graphic xlink:href="pone.0247445.e019.jpg" id="pone.0247445.e019g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M19"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(16)</label></disp-formula>
This is indicated by the dash-dotted curve in <xref ref-type="fig" rid="pone.0247445.g002">Fig 2</xref>. Note that <italic>α</italic>(<italic>t</italic>) does not depend on the value of <italic>I</italic><sub><italic>c</italic></sub>.</p>
                <p>Next we consider the cost function for proceeding from some <italic>S</italic> = <italic>S</italic><sub>0</sub> to some <italic>S</italic> = <italic>S</italic><sub>1</sub> &lt; <italic>S</italic><sub>0</sub> while maintaining <italic>I</italic> = <italic>I</italic><sub><italic>c</italic></sub>. Inserting <xref ref-type="disp-formula" rid="pone.0247445.e019">Eq 16</xref> in <xref ref-type="disp-formula" rid="pone.0247445.e001">Eq 1</xref>, we find
<disp-formula id="pone.0247445.e020"><alternatives><graphic xlink:href="pone.0247445.e020.jpg" id="pone.0247445.e020g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M20"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>d</mml:mi><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mi>τ</mml:mi></mml:mfrac><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(17)</label></disp-formula>
We use this substitution to express the cost function as
<disp-formula id="pone.0247445.e021"><alternatives><graphic xlink:href="pone.0247445.e021.jpg" id="pone.0247445.e021g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M21"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>K</mml:mi><mml:mo>=</mml:mo><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:munderover><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.166667em"/><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mi>τ</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:mfrac><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:munderover><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>S</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.166667em"/><mml:mi>d</mml:mi><mml:mi>S</mml:mi><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(18)</label></disp-formula>
Hence if <italic>S</italic><sub>0</sub> and <italic>S</italic><sub>1</sub> are fixed, <italic>I</italic><sub><italic>c</italic></sub> must be as large as possible to minimize <italic>K</italic>. This now guides our heuristic: we should control <italic>α</italic> such as to maintain <italic>I</italic> = <italic>I</italic><sub><italic>h</italic></sub> for as long as possible.</p>
                <p>If our guess is valid, the trajectory we have to follow in order to optimally control the pandemic is the one indicated as the solid curve in <xref ref-type="fig" rid="pone.0247445.g002">Fig 2</xref>. It starts at (<italic>S</italic>, <italic>I</italic>) = (1, 0) and proceeds until <italic>I</italic> = <italic>I</italic><sub><italic>h</italic></sub> is reached. This completes phase I of the process, during which we set <italic>α</italic> = 0. Mitigation measures are then deployed, such that <italic>α</italic> jumps upwards to the dash-dotted curve. It follows that curve all through phase II, hence keeping <italic>I</italic> = <italic>I</italic><sub><italic>h</italic></sub> constant. As <italic>S</italic> decreases, <italic>α</italic> is gradually reduced until it reaches zero at the end of phase II. All through phase III, <italic>α</italic> is maintained at zero, while <italic>I</italic> gradually decays to zero because <italic>R</italic> &lt; 1. This ends the pandemic.</p>
              </sec>
              <sec id="sec004">
                <title>Validation of the solution</title>
                <p>We now proceed to verify our heuristic solution. We focus on phase II, as this is where the pandemic will spend the most amount of time. To do this we ask the question: Is it true that if the pandemic starts with <italic>I</italic><sub>0</sub> = <italic>I</italic><sub><italic>h</italic></sub>, then for all <italic>S</italic><sub>0</sub> &gt; 1/<italic>R</italic><sub>0</sub> and for all the cost functions <italic>f</italic>(<italic>α</italic>(<italic>t</italic>)) such that <inline-formula id="pone.0247445.e022"><alternatives><graphic xlink:href="pone.0247445.e022.jpg" id="pone.0247445.e022g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M22"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>∂</mml:mi><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>∂</mml:mi><mml:mi>α</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>∂</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>∂</mml:mi><mml:msup><mml:mi>α</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, optimal pandemic control must keep <italic>I</italic>(<italic>t</italic>) = <italic>I</italic><sub><italic>h</italic></sub> until <inline-formula id="pone.0247445.e023"><alternatives><graphic xlink:href="pone.0247445.e023.jpg" id="pone.0247445.e023g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M23"><mml:mrow><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula> is reached?</p>
                <p>As we will see, the answer to the above question is yes. We proceed by setting <inline-formula id="pone.0247445.e024"><alternatives><graphic xlink:href="pone.0247445.e024.jpg" id="pone.0247445.e024g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M24"><mml:mrow><mml:msup><mml:mi>α</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0247445.e025"><alternatives><graphic xlink:href="pone.0247445.e025.jpg" id="pone.0247445.e025g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M25"><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mi>τ</mml:mi></mml:mfrac><mml:mi>t</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> for <inline-formula id="pone.0247445.e026"><alternatives><graphic xlink:href="pone.0247445.e026.jpg" id="pone.0247445.e026g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M26"><mml:mrow><mml:mi>t</mml:mi><mml:mo>∈</mml:mo><mml:mo>[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>]</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pone.0247445.e027"><alternatives><graphic xlink:href="pone.0247445.e027.jpg" id="pone.0247445.e027g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M27"><mml:mrow><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mi>τ</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula>. The terminal conditions for the dynamics are given by <inline-formula id="pone.0247445.e028"><alternatives><graphic xlink:href="pone.0247445.e028.jpg" id="pone.0247445.e028g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M28"><mml:mrow><mml:msup><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>. We can substitute the terminal conditions in <xref ref-type="disp-formula" rid="pone.0247445.e011">Eq 10</xref> and get the terminal condition for λ<sub><italic>S</italic></sub> (the terminal condition for λ<sub><italic>I</italic></sub> is given by <xref ref-type="disp-formula" rid="pone.0247445.e014">Eq 13</xref>). The task remains to find <italic>μ</italic>(<italic>t</italic>) such that Eqs <xref ref-type="disp-formula" rid="pone.0247445.e012">11</xref> and <xref ref-type="disp-formula" rid="pone.0247445.e013">12</xref> are satisfied simultaneously.</p>
                <p>Let’s have a look at Eqs <xref ref-type="disp-formula" rid="pone.0247445.e012">11</xref> and <xref ref-type="disp-formula" rid="pone.0247445.e013">12</xref> after making the substitutions. We have
<disp-formula id="pone.0247445.e029"><alternatives><graphic xlink:href="pone.0247445.e029.jpg" id="pone.0247445.e029g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M29"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mo>λ</mml:mo><mml:mo>˙</mml:mo></mml:mover><mml:mi>S</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mrow><mml:mi>τ</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mo>λ</mml:mo><mml:mi>S</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mo>λ</mml:mo><mml:mi>I</mml:mi></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mo>λ</mml:mo><mml:mo>˙</mml:mo></mml:mover><mml:mi>I</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>τ</mml:mi></mml:mfrac><mml:msub><mml:mo>λ</mml:mo><mml:mi>S</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>μ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(19)</label></disp-formula>
and
<disp-formula id="pone.0247445.e030"><alternatives><graphic xlink:href="pone.0247445.e030.jpg" id="pone.0247445.e030g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M30"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mrow><mml:mo/><mml:mfrac><mml:mrow><mml:mi>∂</mml:mi><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>∂</mml:mi><mml:mi>α</mml:mi></mml:mrow></mml:mfrac><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mi>α</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mo>λ</mml:mo><mml:mi>S</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mo>λ</mml:mo><mml:mi>I</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>β</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(20)</label></disp-formula>
One can hence find the Lagrange parameter <italic>μ</italic>(<italic>t</italic>) as
<disp-formula id="pone.0247445.e031"><alternatives><graphic xlink:href="pone.0247445.e031.jpg" id="pone.0247445.e031g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M31"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>μ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mo>λ</mml:mo><mml:mi>S</mml:mi></mml:msub><mml:mi>τ</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>∂</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>∂</mml:mi><mml:msup><mml:mi>α</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mo>*</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(21)</label></disp-formula>
Lastly, there is also the issue of non-negativity of <italic>μ</italic>. If we assume the convexity of <italic>f</italic> we have <inline-formula id="pone.0247445.e032"><alternatives><graphic xlink:href="pone.0247445.e032.jpg" id="pone.0247445.e032g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M32"><mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mi>∂</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>∂</mml:mi><mml:msup><mml:mi>α</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. Hence the second summand in <xref ref-type="disp-formula" rid="pone.0247445.e031">Eq 21</xref> is non-negative. <inline-formula id="pone.0247445.e033"><alternatives><graphic xlink:href="pone.0247445.e033.jpg" id="pone.0247445.e033g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M33"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>∂</mml:mi><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>∂</mml:mi><mml:mi>α</mml:mi></mml:mrow></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> also implies that λ<sub><italic>S</italic></sub> is monotonically increasing (Eqs <xref ref-type="disp-formula" rid="pone.0247445.e029">19</xref> and <xref ref-type="disp-formula" rid="pone.0247445.e030">20</xref>). If the cost of zero control is zero, then the terminal condition <xref ref-type="disp-formula" rid="pone.0247445.e011">Eq 10</xref> implies that <inline-formula id="pone.0247445.e034"><alternatives><graphic xlink:href="pone.0247445.e034.jpg" id="pone.0247445.e034g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M34"><mml:mrow><mml:msub><mml:mo>λ</mml:mo><mml:mi>S</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, thereby implying λ<sub><italic>S</italic></sub>(<italic>t</italic>) ≤ 0 in the interval <inline-formula id="pone.0247445.e035"><alternatives><graphic xlink:href="pone.0247445.e035.jpg" id="pone.0247445.e035g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M35"><mml:mrow><mml:mo>[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>]</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>. This shows that for time independent cost functions <italic>f</italic> under the assumptions that <inline-formula id="pone.0247445.e036"><alternatives><graphic xlink:href="pone.0247445.e036.jpg" id="pone.0247445.e036g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M36"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>∂</mml:mi><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>∂</mml:mi><mml:mi>α</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>∂</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>∂</mml:mi><mml:msup><mml:mi>α</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> and <italic>f</italic>(0) = 0 our heuristic solution is optimal in phase II.</p>
              </sec>
              <sec id="sec005">
                <title>Numerical results</title>
                <p>We have shown that an optimal trajectory starting on the boundary (<italic>I</italic><sub>0</sub> = <italic>I</italic><sub><italic>h</italic></sub>) remains on that boundary. To obtain optimal control trajectories for arbitrary initial conditions, we perform direct numerical optimization using the software library PSOPT [<xref rid="pone.0247445.ref016" ref-type="bibr">16</xref>]. In <xref ref-type="fig" rid="pone.0247445.g003">Fig 3</xref> we show the numerical solutions to the control problem <xref ref-type="disp-formula" rid="pone.0247445.e009">Eq (8)</xref> for various cost functions <italic>f</italic><sub><italic>i</italic></sub>(<italic>α</italic>(<italic>t</italic>)) ∈ {<italic>α</italic>(<italic>t</italic>), <italic>α</italic><sup>2</sup>(<italic>t</italic>), <italic>α</italic><sup>3</sup>(<italic>t</italic>)}.</p>
                <fig id="pone.0247445.g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0247445.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Numerical solutions for optimal control.</title>
                    <p>Optimal control trajectories for different cost functions <italic>f</italic><sub><italic>i</italic></sub>(<italic>α</italic>(<italic>t</italic>)) ∈ {<italic>α</italic>(<italic>t</italic>), <italic>α</italic><sup>2</sup>(<italic>t</italic>), <italic>α</italic><sup>3</sup>(<italic>t</italic>)}. The corresponding optimal terminal times, <inline-formula id="pone.0247445.e037"><alternatives><graphic id="pone.0247445.e037g" xlink:href="pone.0247445.e037"/><mml:math id="M37"><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup></mml:math></alternatives></inline-formula>, are determined as {65.99<italic>τ</italic>, 66.13<italic>τ</italic>, 66.31<italic>τ</italic>}. <italic>I</italic><sub>0</sub> = 0.0025, <italic>I</italic><sub><italic>h</italic></sub> = 0.01, <italic>R</italic><sub>0</sub> = 3, <inline-formula id="pone.0247445.e038"><alternatives><graphic id="pone.0247445.e038g" xlink:href="pone.0247445.e038"/><mml:math id="M38"><mml:mrow><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. <italic>R</italic><sub>∞</sub> is the asymptotic reproduction number for <italic>t</italic> → ∞, given by <italic>R</italic><sub>∞</sub> = −<italic>W</italic>(exp(−1 − <italic>R</italic><sub>0</sub>
<italic>I</italic><sub><italic>h</italic></sub>)), with the Lambert <italic>W</italic> function.</p>
                  </caption>
                  <graphic xlink:href="pone.0247445.g003"/>
                </fig>
                <p>Clearly, in all scenarios the optimal trajectory <italic>I</italic>* reaches the threshold value <italic>I</italic><sub><italic>h</italic></sub> and remains there until <inline-formula id="pone.0247445.e039"><alternatives><graphic xlink:href="pone.0247445.e039.jpg" id="pone.0247445.e039g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M39"><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> is reached (phase II). Phase I, however, depends on the cost function applied. For linear costs, <italic>α</italic>(<italic>t</italic>) = 0 until <italic>I</italic> = <italic>I</italic><sub><italic>h</italic></sub>. With higher order cost terms, we observe non-zero control from the very beginning (see <xref ref-type="fig" rid="pone.0247445.g003">Fig 3</xref>). This is to reduce the amount of time spent at large control values <italic>α</italic> and thereby the total integrated costs. The optimal terminal time <inline-formula id="pone.0247445.e040"><alternatives><graphic xlink:href="pone.0247445.e040.jpg" id="pone.0247445.e040g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M40"><mml:msubsup><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mo>*</mml:mo></mml:msubsup></mml:math></alternatives></inline-formula> increases with the order of the cost function (see <xref ref-type="fig" rid="pone.0247445.g003">Fig 3</xref>). We should note, however, that the influence of the functional form of <italic>f</italic>(<italic>α</italic>(<italic>t</italic>)), as expressed in the different shapes of the numerically derived curves, is minute, since the time axis is logarithmic, and the deviations are noticeable only during a very small fraction of time. Hence we see that the influence of the cost function, which corresponds to the chosen mitigation strategy, is finite, but can be regarded as <italic>negligible</italic> for practical purposes.</p>
              </sec>
            </sec>
            <sec id="sec006">
              <title>Duration of the pandemic</title>
              <p>If immune response acquired after recovery from an infection is permanent, the pandemic will last until herd immunity is reached at the end of phase II. This is when <italic>S</italic>(<italic>t</italic>) = <italic>S</italic><sub>1</sub> = 1/<italic>R</italic><sub>0</sub>, as indicated by the left vertical dotted line in <xref ref-type="fig" rid="pone.0247445.g002">Fig 2</xref>. This is the start of phase III, in which the number of infected citizens decays with no mitigation measures anymore in place (i.e., at <italic>α</italic> = 0). We will now discuss the time we expect it to take until this point is reached. Using <xref ref-type="disp-formula" rid="pone.0247445.e020">Eq (17)</xref> with <italic>I</italic><sub><italic>c</italic></sub> = <italic>I</italic><sub><italic>h</italic></sub>, we can write
<disp-formula id="pone.0247445.e041"><alternatives><graphic xlink:href="pone.0247445.e041.jpg" id="pone.0247445.e041g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M41"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mi>τ</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:mfrac><mml:mspace width="0.166667em"/><mml:mi>d</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(22)</label></disp-formula>
and hence for the total duration of the pandemic, <italic>T</italic><sub>0</sub>, until herd immunity is reached,
<disp-formula id="pone.0247445.e042"><alternatives><graphic xlink:href="pone.0247445.e042.jpg" id="pone.0247445.e042g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M42"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mi>τ</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:mfrac><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:munderover><mml:mi>d</mml:mi><mml:mi>S</mml:mi><mml:mo>≈</mml:mo><mml:mfrac><mml:mi>τ</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:mfrac><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mo>)</mml:mo><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(23)</label></disp-formula>
Here we have exploited the fact that in all cases of practical relevance, <italic>I</italic><sub><italic>h</italic></sub> will be very small as compared to unity. Consequently, the duration of phase I will be very small as compared to phase II, such that the evaluation of the true duration of phase I is of minor importance. As a very good approximation, we have simply set <italic>S</italic><sub>0</sub> = 1 and neglected the impact of <italic>α</italic>(<italic>t</italic>) on the dynamics for the short period of phase I.</p>
              <sec id="sec007">
                <title>Influence of immune response decay</title>
                <p>The introductory discussion was based on the idea that recovered patients stay immune for all times. However, it is well known that for some diseases, in particular of the SARS-CoV type, the immune response tends to decay after some time [<xref rid="pone.0247445.ref017" ref-type="bibr">17</xref>]. Hence there is some finite probability that recovered patients become susceptible again.</p>
                <p>We now assume that the transition from the recovered to the susceptible state can be described as a Poisson process. In other words, we assume the probability that a randomly chosen, formerly infected citizen becomes susceptible in a time interval [<italic>t</italic>, <italic>t</italic> + <italic>dt</italic>] to be proportional to <italic>dt</italic> and independent of <italic>t</italic>. This modifies the dynamical system (<xref ref-type="disp-formula" rid="pone.0247445.e001">1</xref>) to
<disp-formula id="pone.0247445.e043"><alternatives><graphic xlink:href="pone.0247445.e043.jpg" id="pone.0247445.e043g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M43"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>∂</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mi>S</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>−</mml:mo><mml:mi>β</mml:mi><mml:mi>S</mml:mi><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>ρ</mml:mi></mml:mfrac><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:mi>I</mml:mi><mml:mo>)</mml:mo><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd/></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>∂</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mi>I</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi>β</mml:mi><mml:mi>S</mml:mi><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:mfrac><mml:mi>I</mml:mi><mml:mi>τ</mml:mi></mml:mfrac><mml:mspace width="0.166667em"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(24)</label></disp-formula>
with <italic>β</italic> = <italic>β</italic><sub>0</sub>(1 − <italic>α</italic>), and <italic>ρ</italic> the average life time of the immune state, averaged over all formerly infected individuals. Note that we conceptually include those who fell victim to the disease and thus do not become susceptible again. Their contribution to the average resusceptibilization frequency is zero, which merely increases the average immune lifetime, <italic>ρ</italic>. From the data in [<xref rid="pone.0247445.ref017" ref-type="bibr">17</xref>], we find that after three years the average IgG immune response against SARS-CoV had decayed to 55.6 percent. For a corresponding Poissonian process we can estimate <italic>ρ</italic> ≈ 931 days.</p>
                <p>In <xref ref-type="disp-formula" rid="pone.0247445.e043">Eq 24</xref>, we see immediately that the conditions to fulfill ∂<sub><italic>t</italic></sub><italic>I</italic> = 0 have not changed with respect to <xref ref-type="disp-formula" rid="pone.0247445.e001">Eq 1</xref>. Hence the optimal control trajectory still obeys <inline-formula id="pone.0247445.e044"><alternatives><graphic xlink:href="pone.0247445.e044.jpg" id="pone.0247445.e044g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M44"><mml:mrow><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula>. In phase II, with optimal control, we obtain
<disp-formula id="pone.0247445.e045"><alternatives><graphic xlink:href="pone.0247445.e045.jpg" id="pone.0247445.e045g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M45"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>∂</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mi>τ</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>ρ</mml:mi></mml:mfrac><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>ρ</mml:mi></mml:mfrac><mml:mi>S</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(25)</label></disp-formula>
with the solution
<disp-formula id="pone.0247445.e046"><alternatives><graphic xlink:href="pone.0247445.e046.jpg" id="pone.0247445.e046g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M46"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>ρ</mml:mi><mml:mi>τ</mml:mi></mml:mfrac><mml:mo>)</mml:mo><mml:mo>[</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>t</mml:mi><mml:mo>/</mml:mo><mml:mi>ρ</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>]</mml:mo><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(26)</label></disp-formula></p>
                <p>Again, herd immunity (and hence the end of the pandemic) is reached when <italic>S</italic> = 1/<italic>R</italic><sub>0</sub>, at a time we call <italic>T</italic><sub><italic>r</italic></sub>, referring to resusceptibilization (i.e., decaying immune response). Inserting this into <xref ref-type="disp-formula" rid="pone.0247445.e046">Eq 26</xref> yields
<disp-formula id="pone.0247445.e047"><alternatives><graphic xlink:href="pone.0247445.e047.jpg" id="pone.0247445.e047g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M47"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mi>ρ</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:mo>/</mml:mo><mml:mi>τ</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(27)</label></disp-formula>
and hence
<disp-formula id="pone.0247445.e048"><alternatives><graphic xlink:href="pone.0247445.e048.jpg" id="pone.0247445.e048g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M48"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>ρ</mml:mi><mml:mo form="prefix">ln</mml:mo><mml:mo>[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:mo>/</mml:mo><mml:mi>τ</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>]</mml:mo><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(28)</label></disp-formula>
Although this looks rather awkward, it can be rewritten conveniently in terms of the pandemic duration, <italic>T</italic><sub>0</sub>, which we would find for infinite <italic>ρ</italic>. Defining the variable <italic>X</italic> = <italic>T</italic><sub>0</sub>/(<italic>τ</italic> + <italic>ρ</italic>), we find
<disp-formula id="pone.0247445.e049"><alternatives><graphic xlink:href="pone.0247445.e049.jpg" id="pone.0247445.e049g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M49"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>X</mml:mi></mml:mfrac><mml:mo form="prefix">ln</mml:mo><mml:mo>[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>X</mml:mi><mml:mo>]</mml:mo><mml:mspace width="0.166667em"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(29)</label></disp-formula>
<italic>X</italic> is the total duration of the pandemic if no loss of immunity occurs, divided by the average time it takes for a patient from her infection to the loss of immunity after recovery, <italic>τ</italic> + <italic>ρ</italic>. If immunity lasts very much longer than <italic>T</italic><sub>0</sub>, <italic>X</italic> is small. In this case, the logarithm in <xref ref-type="disp-formula" rid="pone.0247445.e049">Eq 29</xref> can be expanded and we recover <italic>T</italic><sub><italic>r</italic></sub> ≈ <italic>T</italic><sub>0</sub>. If, however, <italic>ρ</italic> is of order <italic>T</italic><sub>0</sub> (remember that <italic>T</italic><sub>0</sub> ≫ <italic>τ</italic> in all relevant cases), <italic>T</italic><sub><italic>r</italic></sub> diverges. This behavior is summarized in <xref ref-type="fig" rid="pone.0247445.g004">Fig 4a</xref>, in which <italic>X</italic> is chosen as the abscissa. We see that the duration of the pandemic becomes uncomfortably large when the total time from infection to resusceptibilization, <italic>τ</italic> + <italic>ρ</italic>, comes close to the pandemic duration with infinite immunity, <italic>T</italic><sub>0</sub> (vertical dotted line).</p>
                <fig id="pone.0247445.g004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0247445.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>Duration of the pandemic and minimum health system capacity.</title>
                    <p>(a) The normalized duration of the pandemic, <italic>T</italic><sub><italic>r</italic></sub>/<italic>T</italic><sub>0</sub>, as a function of the variable <italic>X</italic> = <italic>T</italic><sub>0</sub>/(<italic>τ</italic> + <italic>ρ</italic>) (<xref ref-type="disp-formula" rid="pone.0247445.e049">Eq 29</xref>). (b) Solid curves: The minimum required health system capacity <inline-formula id="pone.0247445.e050"><alternatives><graphic id="pone.0247445.e050g" xlink:href="pone.0247445.e050"/><mml:math id="M50"><mml:msub><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>h</mml:mi></mml:msub></mml:math></alternatives></inline-formula> to reach herd immunity (<xref ref-type="disp-formula" rid="pone.0247445.e051">Eq 30</xref>) as a function of the duration of immunity after recovery, for different values of <italic>R</italic><sub>0</sub> (from 1.5 to 4.0 in steps of 0.5). Dotted curve: limit <italic>R</italic><sub>0</sub> → ∞. Circles represent the scenario for <italic>ρ</italic> = 93<italic>τ</italic>. Open: <italic>I</italic><sub><italic>h</italic></sub> = 0.01. Closed: <italic>I</italic><sub><italic>h</italic></sub> = 0.0025.</p>
                  </caption>
                  <graphic xlink:href="pone.0247445.g004"/>
                </fig>
                <p>We might now ask how many acute infections the health system must be able to deal with in order to reach herd immunity at all. This can be derived by demanding lim<sub><italic>t</italic>→∞</sub>
<italic>S</italic>(<italic>t</italic>) = 1/<italic>R</italic><sub>0</sub> in <xref ref-type="disp-formula" rid="pone.0247445.e046">Eq 26</xref>. It is readily shown that the health system capacity required for reaching herd immunity is given by
<disp-formula id="pone.0247445.e051"><alternatives><graphic xlink:href="pone.0247445.e051.jpg" id="pone.0247445.e051g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M51"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>h</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi>ρ</mml:mi><mml:mi>τ</mml:mi></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(30)</label></disp-formula>
This is shown in <xref ref-type="fig" rid="pone.0247445.g004">Fig 4b</xref> for different values of <italic>R</italic><sub>0</sub>. The dotted curve represents the (unrealistic) limiting case <italic>R</italic><sub>0</sub> → ∞.</p>
                <p>Only with infinite immune response lifetime (<italic>ρ</italic> → ∞), we observe an exponential decay of <italic>I</italic> after herd immunity has been reached (see also <xref ref-type="fig" rid="pone.0247445.g003">Fig 3</xref>). To understand the long time dynamics after mitigation (phase III) for finite <italic>ρ</italic>, we draw the phase portrait (see <xref ref-type="fig" rid="pone.0247445.g005">Fig 5</xref>). There exist two fixed points, (<italic>I</italic><sub>1</sub>, <italic>S</italic><sub>1</sub>) = (0, 1), a saddle for <italic>R</italic><sub>0</sub> ≥ 1, and <inline-formula id="pone.0247445.e052"><alternatives><graphic xlink:href="pone.0247445.e052.jpg" id="pone.0247445.e052g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M52"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>∞</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>∞</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>h</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>, a stable fixed point for <italic>R</italic><sub>0</sub> ≥ 1 (see <xref ref-type="supplementary-material" rid="pone.0247445.s001">S1 Appendix</xref> for details on the linear stability analysis). So for any initial conditions with <italic>I</italic><sub>0</sub> &gt; 0, the uncontrolled system will approach the stationary state, (<italic>I</italic><sub>∞</sub>, <italic>S</italic><sub>∞</sub>). Interestingly, the stationary fraction of infected coincides with the minimal HSS capacity <inline-formula id="pone.0247445.e053"><alternatives><graphic xlink:href="pone.0247445.e053.jpg" id="pone.0247445.e053g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M53"><mml:msub><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>h</mml:mi></mml:msub></mml:math></alternatives></inline-formula> needed to reach herd immunity.</p>
                <fig id="pone.0247445.g005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0247445.g005</object-id>
                  <label>Fig 5</label>
                  <caption>
                    <title>Phase portrait of the uncontrolled SIR model.</title>
                    <p>Phase portrait, <inline-formula id="pone.0247445.e054"><alternatives><graphic id="pone.0247445.e054g" xlink:href="pone.0247445.e054"/><mml:math id="M54"><mml:mrow><mml:mo>(</mml:mo><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mrow><mml:mo>(</mml:mo><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mi>I</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mover accent="true"><mml:mi>S</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mrow><mml:mo>(</mml:mo><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mi>I</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, for the uncontrolled SIR model (<italic>α</italic> = 0) with finite immune response (<xref ref-type="disp-formula" rid="pone.0247445.e043">Eq 24</xref>). The solid green curve shows a trajectory in phase III, with initial conditions (circle) <italic>I</italic><sub>0</sub> = <italic>I</italic><sub><italic>h</italic></sub> (capacity limit) and <italic>S</italic><sub>0</sub> = 1/<italic>R</italic><sub>0</sub> (herd immunity), The dashed curves (orange) show the nullclines, <inline-formula id="pone.0247445.e055"><alternatives><graphic id="pone.0247445.e055g" xlink:href="pone.0247445.e055"/><mml:math id="M55"><mml:mrow><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> (for <italic>S</italic> = 1/<italic>R</italic><sub>0</sub> or <italic>I</italic> = 0), and <inline-formula id="pone.0247445.e056"><alternatives><graphic id="pone.0247445.e056g" xlink:href="pone.0247445.e056"/><mml:math id="M56"><mml:mrow><mml:mover accent="true"><mml:mi>S</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> (for <italic>S</italic> = (1 − <italic>I</italic>)/(<italic>IR</italic><sub>0</sub>
<italic>ρ</italic>/<italic>τ</italic> + 1)). The stable fixed point (diamond) is given by <inline-formula id="pone.0247445.e057"><alternatives><graphic id="pone.0247445.e057g" xlink:href="pone.0247445.e057"/><mml:math id="M57"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>∞</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>h</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, <italic>S</italic><sub>∞</sub> = 1/<italic>R</italic><sub>0</sub>. Parameters: <italic>R</italic><sub>0</sub> = 3, <italic>ρ</italic>/<italic>τ</italic> = 93, <italic>I</italic><sub><italic>h</italic></sub> = 0.01.</p>
                  </caption>
                  <graphic xlink:href="pone.0247445.g005"/>
                </fig>
                <p>We have thus shown that given <inline-formula id="pone.0247445.e058"><alternatives><graphic xlink:href="pone.0247445.e058.jpg" id="pone.0247445.e058g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M58"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>h</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, herd immunity can be reached in finite time during mitigation phase II. After mitigation measures have been released (phase III), <italic>I</italic> converges to <inline-formula id="pone.0247445.e059"><alternatives><graphic xlink:href="pone.0247445.e059.jpg" id="pone.0247445.e059g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M59"><mml:msub><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>h</mml:mi></mml:msub></mml:math></alternatives></inline-formula> in the long time limit. Moreover, <italic>I</italic> remains below <italic>I</italic><sub><italic>h</italic></sub> (see <xref ref-type="fig" rid="pone.0247445.g005">Fig 5</xref>) since re-entering the regime <italic>I</italic> &lt; <italic>I</italic><sub><italic>h</italic></sub> from above would require a trajectory to cross itself (not possible for an autonomous system of ODEs (<xref ref-type="disp-formula" rid="pone.0247445.e043">Eq 24</xref>) with unique solutions).</p>
              </sec>
            </sec>
            <sec id="sec008">
              <title>A few scenarios</title>
              <p>Let us finally consider a few scenarios for some typical parameters, as we have in the current COVID-19 pandemic. The maximum number of known acute infections in Germany in spring 2020 was around 100.000, which was well tolerable for the HSS. Depending upon the percentage of cases which are officially recorded, the actual number of infected citizens may be considerably larger. If we assume a factor of two here, corresponding to 200.000 cases, we have <italic>I</italic><sub><italic>h</italic></sub> ≈ 0.0025 (given ≈80 million citizens in Germany). On the other hand, if there are more, and if we also take into account that the HSS could well take a few more patients, we might also consider a scenario with 800.000 acute infections at a time, corresponding then to <italic>I</italic><sub><italic>h</italic></sub> ≈ 0.01. In both cases we also have to vary the average lifetime of the immune state, <italic>ρ</italic>, and observe its effect on the duration of the pandemic.</p>
              <p>The two sets of scenarios are represented in the graphs in <xref ref-type="fig" rid="pone.0247445.g006">Fig 6</xref>. The remaining fraction of susceptible citizens is shown as the solid curves, while the dashed curves represent the control parameter, <italic>α</italic>. As before, we have assumed <italic>R</italic><sub>0</sub> = 3 for the basic reproduction number. We take the value <italic>ρ</italic> = 931 days mentioned above for another SARS-CoV strain as a reasonable estimate. Using <italic>τ</italic> = ten days, this corresponds to <italic>ρ</italic> = 93<italic>τ</italic>. In order to cover this case, we have used the values <italic>ρ</italic>/<italic>τ</italic> = {50, 93, 200, ∞}. For Germany, an HSS capacity of <italic>I</italic><sub><italic>h</italic></sub> = 0.01 (top (a) graph) would correspond to roughly 32% of hospital beds. We do not consider the need for intensive care units here, one reason being lack of knowledge about the fraction of ICU cases. (500.000 in total) utilized for patients with COVID-19, if we assume a hospitalization rate of 20%. This is a conservative estimate given that the number published by the Robert Koch Institute [<xref rid="pone.0247445.ref018" ref-type="bibr">18</xref>] (17%) is based on reported cases only; the true hospitalization rate might be significantly lower. The bottom (b) graph corresponds to a smaller HSS capacity (<italic>I</italic><sub><italic>h</italic></sub> = 0.0025), for Germany, corresponding to 8% utilization of hospital beds.</p>
              <fig id="pone.0247445.g006" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0247445.g006</object-id>
                <label>Fig 6</label>
                <caption>
                  <title>Typical pandemic scenarios for different average immunity loss times, <italic>ρ</italic>/<italic>τ</italic> ∈ {50, 93, 200, ∞}, corresponding to curves from right to left (or see color code), and different values for <italic>I</italic><sub><italic>h</italic></sub>, namely 0.01 in the top (a) graph and 0.0025 in the bottom (b) graph.</title>
                  <p>Solid curves: <italic>S</italic>(<italic>t</italic>). Dashed curves: <italic>α</italic>(<italic>t</italic>). The fraction of acutely infected citizens is kept at <italic>I</italic><sub><italic>h</italic></sub> in phase II until herd immunity is reached (<italic>S</italic> = 1/<italic>R</italic><sub>0</sub>, horizontal dashed line). If this is successful (if <inline-formula id="pone.0247445.e060"><alternatives><graphic id="pone.0247445.e060g" xlink:href="pone.0247445.e060"/><mml:math id="M60"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>I</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>h</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, see <xref ref-type="disp-formula" rid="pone.0247445.e051">Eq 30</xref>) phase III begins: Mitigation measures are being released (<italic>α</italic> = 0) and <italic>S</italic>(<italic>t</italic>) oscillates around its limiting value <italic>S</italic><sub>∞</sub> = 1/<italic>R</italic><sub>0</sub>. Other parameters: <italic>R</italic><sub>0</sub> = 3, <italic>τ</italic> = 10 days.</p>
                </caption>
                <graphic xlink:href="pone.0247445.g006"/>
              </fig>
              <p>From the steadily decreasing dashed curves representing <italic>α</italic>(<italic>t</italic>), it is obvious that the mitigation measures can be gradually alleviated as time proceeds. In the top (a) graph (<italic>I</italic><sub><italic>h</italic></sub> = 0.01) for infinite immunity (<italic>ρ</italic> → ∞), one would reach the end of mitigation measures after about two years (= 66.7<italic>τ</italic>, with <italic>τ</italic> = 10 days). This is, however, hardly realistic. For the more realistic case, <italic>ρ</italic>/<italic>τ</italic> = 93, it would take about three years (≈ 114.9<italic>τ</italic>). For an HSS capacity of <italic>I</italic><sub><italic>h</italic></sub> = 0.0025, bottom (b) graph, clearly, there would be no chance to ever reach herd immunity for <italic>ρ</italic>/<italic>τ</italic> = 93. Instead, one would not reach any further than <italic>α</italic> ≈ 0.5, which still corresponds to rather harsh measures.</p>
              <p>It should finally be noted that the number of fatalities is limited for all cases where herd immunity is reached. In particular, if <italic>ϕ</italic> is the fraction of fatalities among those which are infected, the fraction of fatalities with respect to the population is <inline-formula id="pone.0247445.e061"><alternatives><graphic xlink:href="pone.0247445.e061.jpg" id="pone.0247445.e061g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M61"><mml:mrow><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> for infinite <italic>ρ</italic>. If <italic>ρ</italic> is finite, we find
<disp-formula id="pone.0247445.e062"><alternatives><graphic xlink:href="pone.0247445.e062.jpg" id="pone.0247445.e062g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M62"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>ϕ</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mfrac><mml:mo>)</mml:mo><mml:mfrac><mml:mrow><mml:mi>ϕ</mml:mi><mml:mo form="prefix">ln</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>X</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>X</mml:mi></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(31)</label></disp-formula>
This is precisely the scaling described by the curve displayed in <xref ref-type="fig" rid="pone.0247445.g004">Fig 4a</xref>, which shows that already well below <italic>X</italic> = 1, the death toll incurred by the herd immunity strategy becomes prohibitively high if immune response decay plays a significant role.</p>
            </sec>
            <sec sec-type="conclusions" id="sec009">
              <title>Conclusions</title>
              <p>We have shown that for a wide class of cost functions, in order to reach herd immunity without vaccination, it provides an optimal control strategy to keep the effective reproduction number, <italic>R</italic>, at unity during the majority of the duration of the pandemic. Deviations which depend upon the specific form of the cost function are limited to a narrow time window and can be considered negligible for practical purposes.</p>
              <p>Reducing <italic>R</italic> can be achieved through various measures, e.g., increased hygiene, physical distancing, or contact tracing [<xref rid="pone.0247445.ref019" ref-type="bibr">19</xref>]. Keeping <italic>R</italic> at the critical value of unity—above which epidemic spreading sets in—is, however, hardly feasible in practice, due to uncertainties as well as observation delays concerning the effects of mitigation measures. Development of robust optimal control scenarios taking such uncertainties into account is left for future investigations.</p>
              <p>In this study, costs incurred at time <italic>t</italic> have been considered local in time. Cost functions nonlocal in time (with a memory kernel) would be an interesting extension but go beyond the scope of this work. Costs associated with the number of infections have not been considered explicitly. Instead we kept the number of infections below an upper bound, e.g., the capacity limit of the health service system (HSS). Of course there are societal costs due to infections even below the limit of the HSS. However, if herd immunity is the goal and vaccination is not available, then there is no way around a fraction of 1 − 1/<italic>R</italic><sub>0</sub> of the population going through the infection. Moreover, the effectiveness of specific mitigation measures can depend on the number of infections; while contact tracing is an efficient measure for low case numbers, local health authorities can be overwhelmed if case numbers are high [<xref rid="pone.0247445.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0247445.ref021" ref-type="bibr">21</xref>]. Therefore, the socio-economic costs for establishing a given reproduction number <italic>R</italic> might depend on <italic>I</italic> as well. Here we focused on simple costs functions as a starting point allowing for analytical treatment.</p>
              <p>Explicit expressions for the expected duration of the pandemic have been given, and we have seen that the duration of the pandemic increases strongly as the average lifetime of the immune state decreases. In particular, we can conclude that in case the immune response to SARS-CoV2 decays in a similar manner as for the formerly encountered SARS-CoV1 strain [<xref rid="pone.0247445.ref017" ref-type="bibr">17</xref>], using infection mediated herd immunity as a vaccination strategy for SARS-CoV2 would require a substantial fraction of health system capacity dedicated to COVID-19 patients (see <xref ref-type="fig" rid="pone.0247445.g006">Fig 6</xref>). However, as a consequence of global mobility there may be more pandemics coming which show different infection and immune response behavior. We therefore think that our results should be borne in mind for future use, as they are of rather general nature.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec010">
              <title>Materials and methods</title>
              <p>Simulation code and data can be found in the following repository: <ext-link ext-link-type="uri" xlink:href="https://github.com/poss-group/covid19-control">https://github.com/poss-group/covid19-control</ext-link>.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec011">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0247445.s001">
                <label>S1 Appendix</label>
                <caption>
                  <title>Detailed derivations.</title>
                  <p>1) First order necessary conditions for optimality. 2) Stability analysis of the uncontrolled SIR model with finite immune response.</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0247445.s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list>
              <title>References</title>
              <ref id="pone.0247445.ref001">
                <label>1</label>
                <mixed-citation publication-type="other">World Health Organization. Report of the who-china joint mission on coronavirus disease 2019 (covid-19); 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf">https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0247445.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Enserink</surname><given-names>M</given-names></name>, <name><surname>Kupferschmidt</surname><given-names>K</given-names></name>. <article-title>With COVID-19, modeling takes on life and death importance</article-title>. <source>Science</source>. <year>2020</year>;<volume>367</volume>:<fpage>1414</fpage><pub-id pub-id-type="doi">10.1126/science.367.6485.1414-b</pub-id><?supplied-pmid 32217707?><pub-id pub-id-type="pmid">32217707</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247445.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Dehning</surname><given-names>J</given-names></name>, <name><surname>Zierenberg</surname><given-names>J</given-names></name>, <name><surname>Spitzner</surname><given-names>FP</given-names></name>, <name><surname>Wibral</surname><given-names>M</given-names></name>, <name><surname>Neto</surname><given-names>JP</given-names></name>, <name><surname>Wilczek</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions</article-title>. <source>Science</source>. <year>2020</year>;<volume>369</volume> (<issue>6500</issue>). <pub-id pub-id-type="doi">10.1126/science.abb9789</pub-id>
<?supplied-pmid 32414780?><pub-id pub-id-type="pmid">32414780</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247445.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Hethcote</surname><given-names>HW</given-names></name>. <article-title>The mathematics of infectiuous diseases</article-title>. <source>SIAM Review</source>. <year>2000</year>;<volume>42</volume>:<fpage>599</fpage>–<lpage>653</lpage>. <pub-id pub-id-type="doi">10.1137/S0036144500371907</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247445.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Harko</surname><given-names>T</given-names></name>, <name><surname>Lobo</surname><given-names>FSN</given-names></name>, <name><surname>Mak</surname><given-names>MK</given-names></name>. <article-title>Exact analytical solutions of the Susceptible-Infected-Recovered (SIR) epidemic model and of the SIR model with equal death and birth rates</article-title>. <source>Applied Mathematics and Computation</source>. <year>2014</year>;<volume>236</volume>:<fpage>184</fpage>–<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1016/j.amc.2014.03.030</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247445.ref006">
                <label>6</label>
                <mixed-citation publication-type="other">Gros C, Valenti R, Schneider L, Valenti K, Gros D. Containment efficiency and control strategies for the Corona pandemic costs; 2021. Available from: <ext-link ext-link-type="uri" xlink:href="https://arXiv.org/abs/2004.00493">https://arXiv.org/abs/2004.00493</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0247445.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Zlatić</surname><given-names>V</given-names></name>, <name><surname>Barjašić</surname><given-names>I</given-names></name>, <name><surname>Kadović</surname><given-names>A</given-names></name>, <name><surname>Štefančić</surname><given-names>H</given-names></name>, <name><surname>Gabrielli</surname><given-names>A</given-names></name>. <article-title>Bi-stability of SUDR+ K model of epidemics and test kits applied to COVID-19</article-title>. <source>Nonlinear Dynamics</source>. <year>2020</year>;<volume>101</volume>(<issue>3</issue>):<fpage>1635</fpage>–<lpage>1642</lpage>. <pub-id pub-id-type="doi">10.1007/s11071-020-05888-w</pub-id>
<?supplied-pmid 32839639?><pub-id pub-id-type="pmid">32839639</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247445.ref008">
                <label>8</label>
                <mixed-citation publication-type="other">Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. Imperial College London; 2020. Available from: <ext-link ext-link-type="uri" xlink:href="http://spiral.imperial.ac.uk/handle/10044/1/77482">http://spiral.imperial.ac.uk/handle/10044/1/77482</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0247445.ref009">
                <label>9</label>
                <mixed-citation publication-type="other">Perkins A, Espana G. Optimal control of the COVID-19 pandemic with non-pharmaceutical interventions. Epidemiology; 2020. Available from: <ext-link ext-link-type="uri" xlink:href="http://medrxiv.org/lookup/doi/10.1101/2020.04.22.20076018">http://medrxiv.org/lookup/doi/10.1101/2020.04.22.20076018</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0247445.ref010">
                <label>10</label>
                <mixed-citation publication-type="other">Djidjou-Demasse R, Michalakis Y, Choisy M, Sofonea MT, Alizon S. Optimal COVID-19 epidemic control until vaccine deployment. Infectious Diseases (except HIV/AIDS); 2020. Available from: <ext-link ext-link-type="uri" xlink:href="http://medrxiv.org/lookup/doi/10.1101/2020.04.02.20049189">http://medrxiv.org/lookup/doi/10.1101/2020.04.02.20049189</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0247445.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Gayle</surname><given-names>AA</given-names></name>, <name><surname>Wilder-Smith</surname><given-names>A</given-names></name>, <name><surname>Rocklöv</surname><given-names>J</given-names></name>. <article-title>The reproductive number of COVID-19 is higher compared to SARS coronavirus</article-title>. <source>Journal of Travel Medicine</source>. <year>2020</year>;<volume>27</volume>(<issue>2</issue>):<fpage>taaa021</fpage><pub-id pub-id-type="doi">10.1093/jtm/taaa021</pub-id><?supplied-pmid 32052846?><pub-id pub-id-type="pmid">32052846</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247445.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>He</surname><given-names>X</given-names></name>, <name><surname>Lau</surname><given-names>EH</given-names></name>, <name><surname>Wu</surname><given-names>P</given-names></name>, <name><surname>Deng</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Hao</surname><given-names>X</given-names></name>, <etal>et al</etal><article-title>Temporal dynamics in viral shedding and transmissibility of COVID-19</article-title>. <source>Nature Medicine</source>. <year>2020</year>;<volume>26</volume>(<issue>5</issue>):<fpage>672</fpage>–<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0869-5</pub-id>
<?supplied-pmid 32296168?><pub-id pub-id-type="pmid">32296168</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247445.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Parshani</surname><given-names>R</given-names></name>, <name><surname>Carmi</surname><given-names>S</given-names></name>, <name><surname>Havlin</surname><given-names>S</given-names></name>. <article-title>Epidemic Threshold for the Susceptible-Infectious-Susceptible Model on Random Networks</article-title>. <source>Physical Review Letters</source>. <year>2010</year>;<volume>104</volume>:<fpage>258701</fpage><pub-id pub-id-type="doi">10.1103/PhysRevLett.104.258701</pub-id><?supplied-pmid 20867419?><pub-id pub-id-type="pmid">20867419</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247445.ref014">
                <label>14</label>
                <mixed-citation publication-type="other">Kuhn HW, Tucker AW. Nonlinear Programming. In: Proceedings of the Second Berkeley Symposium on Mathematical Statistics and Probability. Berkeley, Calif.: University of California Press; 1951. p. 481–492. Available from: <ext-link ext-link-type="uri" xlink:href="https://projecteuclid.org/euclid.bsmsp/1200500249">https://projecteuclid.org/euclid.bsmsp/1200500249</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0247445.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Mangasarian</surname><given-names>OL</given-names></name>. <article-title>Sufficient Conditions for the Optimal Control of Nonlinear Systems</article-title>. <source>SIAM Journal on Control</source>. <year>1966</year>;<volume>4</volume>(<issue>1</issue>):<fpage>139</fpage>–<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1137/0304013</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247445.ref016">
                <label>16</label>
                <mixed-citation publication-type="other">Becerra VM. Solving complex optimal control problems at no cost with PSOPT. In: 2010 IEEE International Symposium on Computer-Aided Control System Design. IEEE; 2010. p. 1391–1396.</mixed-citation>
              </ref>
              <ref id="pone.0247445.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>LP</given-names></name>. <article-title>Duration of Antibody Responses after Severe Acute Respiratory Syndrome</article-title>. <source>Emerging Infectious Diseases</source>. <year>2007</year>;<volume>13</volume>:<fpage>1562</fpage><pub-id pub-id-type="doi">10.3201/eid1310.070576</pub-id><?supplied-pmid 18258008?><pub-id pub-id-type="pmid">18258008</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247445.ref018">
                <label>18</label>
                <mixed-citation publication-type="other">Robert Koch Institute. Coronavirus Disease 2019 (COVID-19). Daily Situation Report of the Robert Koch Institute 29/04/2020; 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-04-29-en.pdf?__blob=publicationFile">https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-04-29-en.pdf?__blob=publicationFile</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0247445.ref019">
                <label>19</label>
                <mixed-citation publication-type="other">Bulchandani VB, Shivam S, Moudgalya S, Sondhi SL. Digital Herd Immunity and COVID-19; 2020. Available from: <ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/2004.07237">http://arxiv.org/abs/2004.07237</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0247445.ref020">
                <label>20</label>
                <mixed-citation publication-type="other">Contreras S, Dehning J, Mohr SB, Spitzner FP, Priesemann V. Towards a long-term control of COVID-19 at low case numbers; 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://arXiv.org/abs/2011.11413">https://arXiv.org/abs/2011.11413</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0247445.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Contreras</surname><given-names>S</given-names></name>, <name><surname>Dehning</surname><given-names>J</given-names></name>, <name><surname>Loidolt</surname><given-names>M</given-names></name>, <name><surname>Zierenberg</surname><given-names>J</given-names></name>, <name><surname>Spitzner</surname><given-names>FP</given-names></name>, <name><surname>Urrea-Quintero</surname><given-names>JH</given-names></name>, <etal>et al</etal><article-title>The challenges of containing SARS-CoV-2 via test-trace-and-isolate</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-20699-8</pub-id>
<?supplied-pmid 33452267?><pub-id pub-id-type="pmid">33397941</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <sub-article id="pone.0247445.r001" article-type="aggregated-review-documents">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247445.r001</article-id>
              <title-group>
                <article-title>Decision Letter 0</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pluchino</surname>
                    <given-names>Alessandro</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Alessandro Pluchino</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Alessandro Pluchino</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj001" ext-link-type="doi" xlink:href="10.1371/journal.pone.0247445" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>0</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">12 Jan 2021</named-content>
              </p>
              <p>PONE-D-20-30011</p>
              <p>A control theory approach to optimal pandemic mitigation</p>
              <p>PLOS ONE</p>
              <p>Dear Dr. Heidemann,</p>
              <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
              <p>Please submit your revised manuscript by Feb 05 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
              <p>Please include the following items when submitting your revised manuscript:</p>
              <p>
                <list list-type="bullet">
                  <list-item>
                    <p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
                  </list-item>
                  <list-item>
                    <p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
                  </list-item>
                  <list-item>
                    <p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
                  </list-item>
                </list>
              </p>
              <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
              <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p>
              <p>We look forward to receiving your revised manuscript.</p>
              <p>Kind regards,</p>
              <p>Alessandro Pluchino</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Journal Requirements:</p>
              <p>When submitting your revision, we need you to address these additional requirements.</p>
              <p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
              <p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p>
              <p>
                <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
              </p>
              <p>2. Thank you for stating the following in the Acknowledgments Section of your manuscript:</p>
              <p>"P. G., S. H., and K. M. H. gratefully acknowledge support from the Max Planck Society."</p>
              <p>We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.</p>
              <p>a. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:</p>
              <p> "The author(s) received no specific funding for this work."</p>
              <p>b. Please include your amended statements within your cover letter; we will change the online submission form on your behalf.</p>
              <p>[Note: HTML markup is below. Please do not edit.]</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Partly</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>2. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: N/A</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>5. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: In effect, the authors examine the incurring costs of Corona when</p>
              <p>the level of infections is kept at the boundary of the medical capabilities.</p>
              <p>This is a valid investigation which should be published. There are however</p>
              <p>a few points.</p>
              <p>(a) Figures are of --very-- low quality (resolution). Figure captions are highly</p>
              <p>insufficient. For example, in Fig. 1 the cost function f(alpha) is mentioned as</p>
              <p>'defined somewhere in the text'. Suggesting that the reader should take the</p>
              <p>trouble to search for her/him-self. That is arrogant.</p>
              <p>(b) Herd immunity is taken at the endpoint. In reality, the outbreak will take</p>
              <p>substantially longer, unit I(t)=0. There are not estimates about the costs</p>
              <p>incurring after the herd immunity point. Without this estimate, the paper cannot</p>
              <p>be published.</p>
              <p>(c) The incurring costs are taken to instantaneous. In reality, a certain level</p>
              <p>of containment may be ok for a few weeks, but disastrous if uphold for many</p>
              <p>years, as suggested by the authors. For example, for a few weeks/month</p>
              <p>business may close and reopen, but not after many years. The authors should</p>
              <p>clearly state that they propose a duration of 4-6 years (you need to include the</p>
              <p>post-here period!) for Germany. The issue of additional costs incurring for</p>
              <p>prolong lockdowns need to be discussed.</p>
              <p>Reviewer #2: This manuscript introduce a control theory approach to identify optimal pandemic mitigation strategies based on the framework of homogeneous susceptible-infected-recovered (SIR) models. It provides an optimal control strategy. Optimality is derived and verified by variational and numerical methods for a number of model cost functions. And also they discussed in terms of the feasibility of strategies based on herd immunity. It has certain theoretical guiding significance.</p>
              <p>**********</p>
              <p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: No</p>
              <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
              <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
            </body>
          </sub-article>
          <sub-article id="pone.0247445.r002" article-type="author-comment">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247445.r002</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 0</article-title>
              </title-group>
              <related-article id="rel-obj002" ext-link-type="doi" xlink:href="10.1371/journal.pone.0247445" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">5 Feb 2021</named-content>
              </p>
              <p>Dear Prof. Pluchino, Dear Reviewers,</p>
              <p>We highly appreciate your comments regarding our manuscript. Please find our detailed response in the separate file "Letter to the Reviewers".</p>
              <p>Kind regards,</p>
              <p>–Knut Heidemann.</p>
              <supplementary-material content-type="local-data" id="pone.0247445.s002">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">response-to-reviewers.pdf</named-content></p>
                </caption>
                <media xlink:href="pone.0247445.s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article id="pone.0247445.r003" article-type="editor-report">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247445.r003</article-id>
              <title-group>
                <article-title>Decision Letter 1</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pluchino</surname>
                    <given-names>Alessandro</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Alessandro Pluchino</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Alessandro Pluchino</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj003" ext-link-type="doi" xlink:href="10.1371/journal.pone.0247445" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">8 Feb 2021</named-content>
              </p>
              <p>A control theory approach to optimal pandemic mitigation</p>
              <p>PONE-D-20-30011R1</p>
              <p>Dear Dr. Heidemann,</p>
              <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
              <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
              <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link ext-link-type="uri" xlink:href="http://www.editorialmanager.com/pone/">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
              <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
              <p>Kind regards,</p>
              <p>Alessandro Pluchino</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Additional Editor Comments (optional):</p>
              <p>Reviewers' comments:</p>
            </body>
          </sub-article>
          <sub-article id="pone.0247445.r004" article-type="editor-report">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247445.r004</article-id>
              <title-group>
                <article-title>Acceptance letter</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pluchino</surname>
                    <given-names>Alessandro</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Alessandro Pluchino</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Alessandro Pluchino</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj004" ext-link-type="doi" xlink:href="10.1371/journal.pone.0247445" related-article-type="reviewed-article"/>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">11 Feb 2021</named-content>
              </p>
              <p>PONE-D-20-30011R1 </p>
              <p>A control theory approach to optimal pandemic mitigation </p>
              <p>Dear Dr. Heidemann:</p>
              <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
              <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
              <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
              <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
              <p>Kind regards, </p>
              <p>PLOS ONE Editorial Office Staff</p>
              <p>on behalf of</p>
              <p>Dr. Alessandro Pluchino </p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
            </body>
          </sub-article>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
